Navigation Links
MRIGlobal Engages Industry Expert in Expansion of Molecular Diagnostic Division
Date:9/9/2013

KANSAS CITY, Mo., Sept. 9, 2013 /PRNewswire-USNewswire/ -- MRIGlobal today announced that it is working with Mary E. Holland as part of its continuing expansion of its Molecular Diagnostics Division, which helps commercial diagnostics developers get their products to market faster.

Holland brings years of experience in creating and expanding market segments in Clinical Molecular Diagnostics, with a focus on the development and marketing of core product lines for clinical reference laboratories and diagnostic product manufacturers. She will work closely with Maureen Thornton, Head of Global Business Development for MRIGlobal Molecular Diagnostics, and Meeta Patnaik, M.D.

Holland has served in multiple leadership roles, playing a key role in solidifying brand and product awareness as well as driving profits for multiple companies that went public or to a merger/acquisition by Fortune 500 companies.

She most recently served as Vice President of Sales and Marketing with Madison, Wisconsin-based EraGen Biosciences, now part of Luminex; prior to that she played an integral role in launching Third Wave Technologies. As an entrepreneur, she co-founded Oncogenetics Inc., a comprehensive cancer diagnostic reference laboratory.

"Mary Holland brings diverse and highly relevant experience to the MRIGlobal Molecular Diagnostics Team," said Michael Cassler, Ph.D., Director of MRIGlobal Diagnostics.  "She will help increase our service offering to a broader customer base and further our continued expansion into the commercial diagnostics sector, a priority for our business.  We are both excited and fortunate to have someone of Mary's caliber working for us as a key member of our team." 

About MRIGlobal

MRIGlobal Molecular Diagnostics is a division of MRIGlobal, established in 1944 as Midwest Research Institute. MRIGlobal is based in Kansas City, Mo., operates in nine states and Washington, D.C. MRIGlobal employs more than 500 and manages 2,600-plus workers through management and operations programs with government clients.

MRIGlobal's Diagnostics Division provides assay development for menu expansion in in vitro and molecular diagnostics, validation and clinical testing, sample access and reference material, and platform engineering and integration. MRIGlobal operates a Clinical Laboratory Improvement Amendments (CLIA)-laboratory accredited by the College of American Pathologists. MRIGlobal is ISO 9001 certified and employs current Good Manufacturing Practices and Good Laboratory Practices, and maintains Biosafety Level 3 laboratories.

For more information, visit www.mriglobal.org/diagnostics.


'/>"/>
SOURCE MRIGlobal
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. MRIGlobal, DHMRI Align in Strategic Collaboration
2. NineSigma Engages AtriCure in the Ohio Third Frontier Open Innovation Incentive Program
3. New Resource Provides Herb Industry With Sources of Quality Specifications
4. Garage Start-ups Now Possible in Life Sciences Industry
5. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
6. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
7. Free Job Training: 55 Grants Available to Retrain Workers for Biofuels Industry
8. Hybrid Fuels, Inc. Appoints Industry Expert as New CEO
9. Prolongs Large Scale Manufacturing of Sickle Cell Product to be Headed by Industry Veteran
10. Ohios Bioscience Industry Effort Paying Off With Increase in Graduates and Accolades for the State
11. Hemodialysis Machine Industry 2012 Global & China Market Research Report - ReportsnReports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... Parallel 6 , the leading software as a ... Reach Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine ... team. , Using the CONSULT module, patients and physicians can schedule a face to ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
Breaking Biology News(10 mins):